An assessor blind, randomized, 2-way crossover, two period, single-dose, phase I, active controlled, pharmacokinetic and pharmacodynamic study comparing pegfilgrastim biosimilar with Neulasta® of Amgen (US licensed product) in healthy adult human subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2016
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- 14 Nov 2016 New trial record